RICOVER-60 Randomised study comparing 6 and 8 cycles of chemotherapy with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 14-day intervals (CHOP-14), both with or without the monoclonal anti-CD20 antibody Rituximab in patients aged 61 to 80 years with aggressive Non-Hodgkin’s Lymphoma DSHNHL 1999-1 (RICOVER-60) years months Patient identification number within trial Therapy arm Gender Age (years) IPI factor age>60 years IPI factor LDH>N IPI factor ECOG>1 IPI factor stage III/IV IPI factor extralymphatic involvement > 1 IPI score Extralymphatic involvement Bulky disease B-symptoms Bone marrow involvement Reference pathology diagnosis Event-free survival (months) Event-free survival status Progression-free survival (months) Progression-free survival status Overall survival (months) Overall survival status 6 x CHOP-14 8 x CHOP-14 6 x CHOP-14 + 8xR 8 x CHOP-14 + 8xR male female age <= 60 years age > 60 years LDH <= N LDH > N ECOG <= 1 ECOG > 1 stage I/ II stage III/ IV E <= 1 E > 1 no yes no yes no yes no yes centroblastic immunoblastic plasmoblastic anaplastic large cell (ALC) T-cell-rich B-cell lymphoma DLBCL NOS prim. mediast. B-cell lymphoma follicular lymphoma III° follicular lymphoma III° + DLBL lymphoblastic precursor B-cell Burkitt‘s lymphoma Burkitt-like Mantle cell lymphoma (blastic) Mantle cell lymphoma\, classical type aggressive marginal zone lymphoma B-cell NOS B-cell\, Unclassified (techn. insufficient mat.) AIL-type extranodal NK nasal type low grade NHL no lymphoma Hodgkin‘s disease censored event censored event censored event